TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04831398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: A 5mg dose of melatonin spay will be delivered sublingually.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
Study: NCT05769452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open IV catheter (BD Insyte™ Autoguard™)
Description: BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
Study: NCT04810351

Intervention type: OTHER
Intervention: observational study
Description: There is no intervention. It is an observational study

Intervention type: OTHER
Intervention: observational study
Description: There is no intervention. It is an observational study
Study: NCT06439758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg/day for 6 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle
Description: Dietary lifestyle modifications
Study: NCT06687434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simplified qualitative meal size estimation
Description: participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
Study: NCT05316857

Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib + Rifampin
Description: Orelabrutinib + Rifampin

Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib + Itraconazole
Description: Orelabrutinib + Itraconazole
Study: NCT04396717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pritumumab
Description: Pritumumab IgG1 human monoclonal antibody
Study: NCT05144243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection (SC)
Study: NCT06157840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth application and sleep health education
Description: Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplified mHealth application and sleep health education
Description: Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
Study: NCT05337501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting data
Description: Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
Study: NCT05855629

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule
Description: Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule
Description: Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg

Intervention type: DRUG
Group type: OTHER
Intervention: Topical Adapalene, Benzoyl Peroxide Gel
Description: Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml

Intervention type: DRUG
Group type: OTHER
Intervention: Topical Adapalene, Benzoyl Peroxide Gel
Description: Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
Study: NCT05264805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: 20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Study: NCT05203003

Intervention type: OTHER
Intervention: Assessment of MRD
Description: Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration.
Study: NCT05308654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet
Study: NCT04283097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPG-818
Description: The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
Study: NCT05308654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule
Study: NCT06625047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Complete in-person assessment visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: Complete telehealth assessment visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04951817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
Study: NCT05273892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Activity + Sleep
Description: Personalized lifestyle behavior change counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet + Activity
Description: Personalized lifestyle behavior change counselling
Study: NCT05234346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg 5-ALAPhosphate + SFC
Description: 2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Description for the intervention
Study: NCT06697756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-effort resistance exercise training
Description: Six sets per exercise, 8 repetitions per set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-effort resistance exercise training
Description: Three sets per exercise, 4 repetitions per set.
Study: NCT06696729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Mirabilite Application for Postoperative Gastrointestinal Patients
Description: Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Postoperative Care for Gastrointestinal Patients
Description: Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
Study: NCT06303622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-USG fusion approach
Description: MRI-USG fusion approach prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-guided approach
Description: Cognitive-guided approach prostate biopsy
Study: NCT06701890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: 16 mL at inclusion 16 mL at 1 month after return from travel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal sample collection
Description: 1 sample at inclusion~1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel
Study: NCT06700863

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Radiotherapy for Head and Neck Cancer Patients

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Radiotherapy for Head and Neck Cancer Patients

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Radiotherapy for Head and Neck Cancer Patients

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Radiotherapy for Head and Neck Cancer Patients
Study: NCT06700785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine butyrate
Description: Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Butyrate
Description: Oral sodium butyrate supplement.
Study: NCT04545814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
Study: NCT06700785

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tributyrin
Description: Oral tributyrin supplement.
Study: NCT06700837

Intervention type: OTHER
Intervention: Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea
Description: To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
Study: NCT06700902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Action
Description: Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
Study: NCT06395584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: White Light LED
Description: Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Light LED
Description: Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
Study: NCT06702189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
Study: NCT05166252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time out from smartphone use during meal time
Description: One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: The same as the experimental condition but without a timeout from smartphone use.
Study: NCT05769673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implant
Description: Placement of a dental implant on the edentulous ridge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of dental implant
Description: Placement of a dental implant on the edentulous ridge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of stock healing abutment
Description: Placement of stock healing abutment after implant has been placed on the edentulous ridge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of customized CAD/CAM healing abutment
Description: Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
Study: NCT06460701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: m-CIMT without Kinesio taping
Description: Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-CIMT along with kinesiotaping
Description: Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week
Study: NCT05041166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [13C] Pyruvate
Description: Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [13C] Pyruvate
Description: Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
Study: NCT03949725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hans Kai Program
Description: In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
Study: NCT06521346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active cycle breathing technique
Description: The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) FET and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine care delivers after extubating such as percussion or chest physiotherapy
Study: NCT05169879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronal flaring
Description: early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non coronal flaring
Description: No coronal flaring will be performed
Study: NCT06317805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic treprostinil sodium + Standard of Care (Double Oral)
Description: Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care - Double Oral
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Double Oral
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Study: NCT01070290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 120 mg capsule administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, capecitabine or irinotecan
Description: Investigator's choice or oxaliplatin, capecitabine or irinotecan
Study: NCT06531759

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: Fentanyl soaked nasal packs.
Study: NCT06431620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone
Description: recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
Study: NCT06288815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral fluid
Description: Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid
Description: Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual
Study: NCT06171867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PNEUMACRIT
Description: Monitoring of breathing